Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme
Celularity to leverage Palantir’s next generation software and computational capabilities with their deep cellular data set to accelerate research and development activities Partnership includes equity investment by Palantir in Celularity Investment, combined with previously announced PIPE investment, brings over $100 million in new funding to Celularity FLORHAM PARK, N.J., May 05, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and Palantir Technologies Inc. (NYSE: PLTR), a software company that builds enterprise platforms, will form a multi-year strategic...
NEW YORK, April 16, 2021 /PRNewswire/ — On April 14, 2021, GX Acquisition Corp. (“GX”) (NASDAQ: “GXGX”), provided information regarding a proposal to amend GX’s amended and restated certificate of incorporation (the “Charter”) to extend the date by which GX has to complete its initial business combination (the “Extension”) from May 23, 2021 to July 31, 2021. The Charter currently provides that GX has 24 months from the closing of its initial public offering (until May 23, 2021) to complete an initial business combination, which is customary for a special purpose acquisition company like GX. As previously announced, in January 2021 GX entered into a definitive merger agreement with Celularity...
FLORHAM PARK, N.J., April 13, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, for the treatment of patients with malignant gliomas. CYNK-001 is currently being investigated in a phase 1 clinical trial (NCT04489420) for the treatment of patients with glioblastoma multiforme (GBM), an indication within the...
Presentations to showcase updates related to multiple Celularity programs in immuno-oncology and infectious disease FLORHAM PARK, N.J., April 09, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, will display multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021. The presentations include one poster highlighting early clinical data of CYNK-001 (unmodified natural killer (NK) cell therapy) in COVID-19, and the other showcasing integration of immune monitoring assays with measurement of minimal residual disease for...
FLORHAM PARK, N.J., March 18, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced that the company has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy, CYNK-001, for the treatment of adults with recurrent glioblastoma multiforme (GBM). CYNK-001 is currently being investigated in multiple clinical trials, including a Phase 1 clinical trial for GBM. “This designation marks a...
FLORHAM PARK, N.J., March 09, 2021 (GLOBE NEWSWIRE) — Celularity Inc. (“Celularity”), a clinical-stage biotechnology company focused on the development of innovative allogeneic placenta-derived cellular therapies, announced that Robert J. Hariri, M.D., Ph.D., founder, Chairperson and Chief Executive Officer of Celularity, will present a corporate overview as well as participate in a fireside chat and panel discussion during the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. Corporate Presentation A pre-recorded presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on March 9, 2021. Fireside Chat Topic: Novel Approaches to Allogeneic...
FLORHAM PARK, N.J., Jan. 20, 2021 /PRNewswire/ — Celularity Inc., a clinical stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, today announced that Robert J. Hariri, M.D., Ph.D., Founder, Chairperson and Chief Executive Officer of Celularity and members of the management team will be participating in a fireside chat at the B. Riley Virtual Oncology Investor Conference on Thursday, January 21, 2021, at 3:30 p.m. ET The live audience is limited to institutional investors, investor relations, and employees of Celularity. Private investors will not be given access to the live conference, but a video recording will be available on the...
FLORHAM PARK, N.J., Jan. 13, 2021 /PRNewswire/ — Celularity Inc., a clinical-stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, today announced that its Lifebank division has released its 100th cord blood stem cell unit for use in an autologous cord blood transplant to treat an eight-year-old patient diagnosed with autism spectrum disorder. Researchers throughout the world are investigating cord blood stem cells as a potential treatment option for autism spectrum disorder. Autism is a complex developmental brain disorder that causes varying degrees of communication difficulties, social and behavioral challenges, and repetitive behaviors. It is estimated that 1 child in every...
Celularity has entered into a definitive merger agreement with GX Acquisition Corp. (Nasdaq: “GXGX”); upon closing, shares of the combined company will be listed on Nasdaq under the ticker symbol “CELU”. Institutional investors and certain individuals have committed to invest approximately $80 million through concurrent equity investments (the “PIPE”). $372 million of total expected proceeds from the PIPE and cash held in GX Acquisition Corp.’s trust account (assuming no stockholder redemptions are effected) upon the closing of the business combination. Celularity stockholders (including Sorrento Therapeutics, affiliates of Bristol Myers Squibb, Starr Insurance Companies, and Dragasac Limited, a wholly owned subsidiary...
FLORHAM PARK, N.J., Dec. 1, 2020 /PRNewswire/ — Celularity announced today that the independent Data Monitoring Committee (DMC) completed the first assessment of the ongoing Phase I/II CYNK-001-COVID-19 (CYNKCOVID) study (https://clinicaltrials.gov/ct2/show/NCT04365101) with CYNK-001 off-the-shelf, allogeneic, natural killer (NK) cell therapy in adults with COVID-19. The DMC confirmed the absence of dose-limiting toxicities and recommended to move forward with the trial. Additionally, there was no evidence of worsening of inflammatory biomarkers observed. The observed clinical findings justify the continuation of the trial. Enrollment is ongoing in this multi-center clinical study with active sites in Arizona, Arkansas, California, New Jersey, and Washington. “We are encouraged that an esteemed group of independent experts...
Load more
F.A.Q
Support Forum
Video Tutorials
Search panel can contain any widgets and shortcodes.
Call us: 0 800 255 22 55
THE NEXT
EVOLUTION IN
CELLULAR
MEDICINE
Contact Us
Celularity is fundamentally altering how we approach the treatment of Cancer, Infectious Diseases, and Degenerative Diseases through continuous, innovative application of new discoveries in cellular medicine.
Celularity Enters into Multi-Year Strategic Partnership with Palantir Technologies
GX Acquisition Corp. Provides Information Regarding Extension of Deadline to Complete Celularity Business Combination
Celularity Receives Orphan Drug Designation for Natural Killer Cell Therapy CYNK-001 in the Treatment of Malignant Gliomas
Celularity Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme
Celularity to Present at H.C. Wainwright Global Life Sciences Conference
Celularity to Present at the B. Riley Securities Virtual Oncology Investor Conference
Celularity Announces Release of 100th Cord Blood Stem Cell Unit by its Lifebank Division
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 (CYNKCOVID) Study